Novel paradigms for drug discovery: computational multitarget screening.
暂无分享,去创建一个
Ram Samudrala | Ekachai Jenwitheesuk | Jeremy A Horst | R. Samudrala | E. Jenwitheesuk | J. Horst | W. V. Van Voorhis | Kasey L. Rivas | Wesley C Van Voorhis | Kasey L Rivas
[1] T. Kawahata,et al. HIV‐1 integrase inhibitory substances from Coleus parvifolius , 2003, Phytotherapy research : PTR.
[2] M. Eisenstein,et al. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. , 2001, Biochemistry.
[3] Y. Pommier,et al. Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase. , 1995, Journal of medicinal chemistry.
[4] Ram Samudrala,et al. Identification of potential multitarget antimalarial drugs. , 2005, JAMA.
[5] M. Baba,et al. Selective inhibition of human cytomegalovirus replication by naphthalenedisulfonic acid derivatives. , 1993, Antiviral research.
[6] K. Metzner,et al. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients , 2007, AIDS.
[7] L. Montagnier,et al. Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. , 1990, Research in virology.
[8] D. Nayak,et al. Role of G protein and protein kinase signalling in influenza virus budding in MDCK cells. , 2002, The Journal of general virology.
[9] L. Mayer,et al. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. , 1993, AIDS research and human retroviruses.
[10] H. Kung,et al. Inhibition of human immunodeficiency virus infectivity by chloroquine. , 1990, AIDS research and human retroviruses.
[11] J.. Virtual screening : a real screening complement to high-throughput screening , 2009 .
[12] L. Collins,et al. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.
[13] J. Craig,et al. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. , 2003, The Journal of antimicrobial chemotherapy.
[14] J. Tomassini,et al. Durhamycin A, a potent inhibitor of HIV Tat transactivation. , 2002, Journal of natural products.
[15] J. Heitman,et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein , 1997, Antimicrobial agents and chemotherapy.
[16] K. Joiner,et al. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology , 1997, Antimicrobial agents and chemotherapy.
[17] M. Wong,et al. Identification, characterization, and gene expression profiling of endotoxin-induced myocarditis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] D. Harrich,et al. Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Target Distinct Phases of Early Reverse Transcription , 2001, Journal of Virology.
[19] Pierre Baldi,et al. Kernels for small molecules and the prediction of mutagenicity, toxicity and anti-cancer activity , 2005, ISMB.
[20] Jun O. Liu,et al. A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.
[21] T. Kawashima,et al. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae , 1992, Antimicrobial Agents and Chemotherapy.
[22] Martin S. Hirsch,et al. Treatment for adult HIV infection. , 2004 .
[23] A. Jouan,et al. Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds. , 1997, Research in virology.
[24] K. C. Srivastava,et al. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. , 1995, Prostaglandins, leukotrienes, and essential fatty acids.
[25] T. Harrison,et al. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. , 1997, The Journal of clinical investigation.
[26] J. Walden,et al. The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[27] A. Mitra,et al. Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein. , 2001, Journal of pharmaceutical sciences.
[28] B. Strom,et al. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector , 2006, AIDS.
[29] Wolfgang Guba,et al. Computational chemistry as an integral component of lead generation. , 2005, Mini reviews in medicinal chemistry.
[30] Ram Samudrala,et al. Rappertk: a versatile engine for discrete restraint-based conformational sampling of macromolecules , 2007, BMC Structural Biology.
[31] Marco Rusnati,et al. Heparin-Mimicking Sulfonic Acid Polymers as Multitarget Inhibitors of Human Immunodeficiency Virus Type 1 Tat and gp120 Proteins , 2007, Antimicrobial Agents and Chemotherapy.
[32] R. Kato,et al. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. , 1999, Journal of medicinal chemistry.
[33] E. Novellino,et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. , 1998, Journal of medicinal chemistry.
[34] Ram Samudrala,et al. PIRSpred: a web server for reliable HIV-1 protein-inhibitor resistance/susceptibility prediction. , 2005, Trends in microbiology.
[35] Jiri Gut,et al. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. , 2006, Journal of medicinal chemistry.
[36] N. Enomoto,et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. , 2004, Biochemical and biophysical research communications.
[37] C. Katlama,et al. Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study , 1997, AIDS.
[38] E. De Clercq,et al. Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores. , 2001, Journal of medicinal chemistry.
[39] H. Ishitsuka,et al. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides. , 1990, Antiviral research.
[40] Tooru Kimura,et al. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. , 2006, Acta crystallographica. Section D, Biological crystallography.
[41] H. Miyoshi,et al. Fumagillin suppresses HIV‐1 infection of macrophages through the inhibition of Vpr activity , 2006, FEBS letters.
[42] Philip E. Bourne,et al. Structural Evolution of the Protein Kinase–Like Superfamily , 2005, PLoS Comput. Biol..
[43] A. Tsatsakis,et al. COMPARISON OF IN VITRO ACTIVITIES OF AMPHOTERICIN, CLOTRIMAZOLE, ECONAZOLE, MICONAZOLE, AND NYSTATIN AGAINST FUSARIUM OXYSPORUM , 2001, Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes.
[44] M. D. Barratt,et al. Prediction of toxicity from chemical structure , 2004, Cell Biology and Toxicology.
[45] G. Kroemer,et al. Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.
[46] K. Ang,et al. In Vivo Antimalarial Activity of the Beta-Carboline Alkaloid Manzamine A , 2000, Antimicrobial Agents and Chemotherapy.
[47] A. Zuckerman,et al. Effects of amphotericin B on hepatitis B virus , 1981, Antimicrobial Agents and Chemotherapy.
[48] N. Moussatché,et al. Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins. , 1998, The Journal of general virology.
[49] S. Laufer,et al. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. , 2001, Pharmacological research.
[50] T. Mexia,et al. Author ' s personal copy , 2009 .
[51] R. Wierenga,et al. The TIM‐barrel fold: a versatile framework for efficient enzymes , 2001, FEBS letters.
[52] A. Li,et al. Screening for human ADME/Tox drug properties in drug discovery. , 2001, Drug discovery today.
[53] E. De Clercq,et al. Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain. , 2000, Bioorganic & medicinal chemistry.
[54] D. McFarland,et al. Cost-Effectiveness of Cotrimoxazole Prophylaxis Among Persons With HIV in Uganda , 2007, Journal of acquired immune deficiency syndromes.
[55] David Vidal,et al. A Novel Search Engine for Virtual Screening of Very Large Databases , 2006, J. Chem. Inf. Model..
[56] L. Wheat,et al. Comparison of the Echinocandin Caspofungin with Amphotericin B for Treatment of Histoplasmosis following Pulmonary Challenge in a Murine Model , 2000, Antimicrobial Agents and Chemotherapy.
[57] Nigel Greene,et al. Computer systems for the prediction of toxicity: an update. , 2002, Advanced drug delivery reviews.
[58] E. De Clercq,et al. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[59] M. Millan. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. , 2004, European journal of pharmacology.
[60] S. L. Le Blancq,et al. Cyclosporin Analogs Inhibit In Vitro Growth of Cryptosporidium parvum , 1998, Antimicrobial Agents and Chemotherapy.
[61] Romualdo Benigni,et al. Designing safer drugs: (Q)SAR-based identification of mutagens and carcinogens. , 2003, Current topics in medicinal chemistry.
[62] John C. Dearden,et al. In silico prediction of drug toxicity , 2003, J. Comput. Aided Mol. Des..
[63] A. Galabov,et al. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. , 1995, Acta virologica.
[64] J. Heitman,et al. Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans, Candida glabrata, and Candida krusei , 2003, Antimicrobial Agents and Chemotherapy.
[65] D. Murry,et al. Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance , 2007 .
[66] M G Rossmann,et al. Comparison of super-secondary structures in proteins. , 1973, Journal of molecular biology.
[67] A. H. Mackenzie. An appraisal of chloroquine. , 1970, Arthritis and rheumatism.
[68] Jiri Gut,et al. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. , 2004, Journal of medicinal chemistry.
[69] E. Clercq. New developments in anti-HIV chemotherapy , 2001 .
[70] B. Gazzard,et al. The cost of antiretroviral drugs and influence on prescribing policies , 2006, International journal of STD & AIDS.
[71] Janusz M. Bujnicki,et al. Angiogenesis Inhibitors Specific for Methionine Aminopeptidase 2 as Drugs for Malaria and Leishmaniasis , 2002, Journal of Biomedical Science.
[72] J. Fantini,et al. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. , 1994, The Journal of biological chemistry.
[73] Darren Vs Green,et al. Virtual screening of chemical libraries for drug discovery , 2008, Expert opinion on drug discovery.
[74] T. Oki,et al. Pradimicins A, B and C: new antifungal antibiotics. I. Taxonomy, production, isolation and physico-chemical properties. , 1990, The Journal of antibiotics.
[75] G. Eliopoulos,et al. In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria , 2000, Antimicrobial Agents and Chemotherapy.
[76] R. Wallace,,et al. Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous Mycobacteria , 2002, Antimicrobial Agents and Chemotherapy.
[77] A. J. Crowle,et al. Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3 , 1990, Antimicrobial Agents and Chemotherapy.
[78] J. Phair,et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. , 1995, The New England journal of medicine.
[79] O. Weislow,et al. Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. , 1994, Journal of medicinal chemistry.
[80] F. Cohen,et al. Searching for New Antimalarial Therapeutics amongst Known Drugs , 2006, Chemical biology & drug design.
[81] T. Oki,et al. Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities. , 1990, The Journal of antibiotics.
[82] Ram Samudrala,et al. Identification of potential HIV-1 targets of minocycline , 2007, Bioinform..
[83] Michael S Saag,et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[84] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[85] Ram Samudrala,et al. Improved accuracy of HIV-1 genotypic susceptibility interpretation using a consensus approach. , 2004, AIDS.
[86] J. Kovacs,et al. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. , 2000, The New England journal of medicine.
[87] C Y Ung,et al. Computer automated prediction of potential therapeutic and toxicity protein targets of bioactive compounds from Chinese medicinal plants. , 2002, The American journal of Chinese medicine.
[88] P Wexler,et al. TOXNET: the National Library of Medicine's toxicology database. , 1995, American family physician.
[89] E. Wagner,et al. The polysulfonated compound suramin blocks adsorption and lateral difusion of herpes simplex virus type-1 in vero cells. , 1999, Virology.
[90] E. Didier. Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro , 1997, Antimicrobial agents and chemotherapy.
[91] J. Luban,et al. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A , 1996, Journal of virology.
[92] H. R. Chang,et al. Activity of minocycline against Toxoplasma gondii infection in mice. , 1991, The Journal of antimicrobial chemotherapy.
[93] S. Moreno,et al. Limitations of a Simplification Antiretroviral Strategy for HIV-Infected Patients with Decreasing Adherence to a Protease Inhibitor Regimen , 2006, HIV clinical trials.
[94] M. Jiang,et al. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. , 1996, Biochemical and biophysical research communications.
[95] J. Utz. SYSTEMIC FUNGAL INFECTIONS AMENABLE TO CHEMOTHERAPY , 1963, Disease-a-month : DM.
[96] G. Scalise,et al. In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. , 1996, The Journal of antimicrobial chemotherapy.
[97] Tim J. P. Hubbard,et al. SCOP: a Structural Classification of Proteins database , 1999, Nucleic Acids Res..
[98] Fusheng Yang,et al. Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.
[99] Jeremy L Jenkins,et al. Virtual screening to enrich hit lists from high‐throughput screening: A case study on small‐molecule inhibitors of angiogenin , 2002, Proteins.
[100] Hui Wang,et al. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. , 2007, Cancer research.
[101] Ram Samudrala,et al. Prediction of HIV-1 Protease Inhibitor Resistance using a Protein–Inhibitor Flexible Docking Approach , 2005, Antiviral therapy.
[102] Y. Pommier,et al. Inhibitors of human immunodeficiency virus integrase. , 1999, Advances in virus research.
[103] M. Gordon,et al. Durhamycin, a Pentaene Antifungal Antibiotic from Streptomyces durhamensis sp. n. , 1966, Applied microbiology.
[104] F. Goñi,et al. Membrane fusion induced by the HIV type 1 fusion peptide: modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds. , 1997, AIDS research and human retroviruses.
[105] F. van Knapen,et al. Susceptibility of Encephalitozoon cuniculi to several drugs in vitro , 1995, Antimicrobial agents and chemotherapy.